Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

William J. Gradishar, MD, and Rita Nanda, MD, on High-Risk Breast Cancer: Results From the I-SPY 2 Trial

Posted: Monday, June 5, 2017

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Rita Nanda, MD, of the University of Chicago, discussed study findings on pembrolizumab plus standard neoadjuvant therapy for high-risk disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.